PCN421 STABILITY OF LIFETIME OVERALL SURVIVAL ESTIMATES OF NIVOLUMAB+IPILIMUMAB IN FIRST-LINE ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA

Multiple database locks (DBLs) with different levels of data maturity have become available for CheckMate-214 (NCT02231749), a phase 3 trial comparing nivolumab+ipilimumab to sunitinib in first-line advanced/metastatic intermediate- or poor-risk renal cell carcinoma (1L RCC). This study assessed the stability of lifetime overall survival (OS) extrapolations based on different DBLs.